Javier Molina-Infante1,2, Pedro Luis Gonzalez-Cordero1, Hal Cliff Ferreira-Nossa1, Pilar Mata-Romero1, Alfredo J Lucendo2,3, Angel Arias2,4. 1. Department of Gastroenterology, Hospital Universitario San Pedro de Alcantara, Cáceres, Spain. 2. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 3. Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain. 4. Research Unit, Hospital General Mancha Centro, Alcazar de San Juan, Ciudad Real, Spain.
Abstract
OBJECTIVES: Epidemiologic studies on eosinophilic esophagitis (EoE) are scarce and patient responders to proton pump inhibitor (PPI) therapy have usually been excluded. We aimed to evaluate population-based incidence rates, prevalence and trends in adult EoE over the past decade, including responders to PPI therapy. METHODS: We conducted an analysis of a prospectively established case registry in the health area of Cáceres, located in midwestern Spain. From the first EoE case diagnosed in 2007, endoscopy and pathology reports up to December 2016 were manually reviewed. A baseline diagnosis of EoE was confirmed upon symptoms of esophageal dysfunction (dysphagia/food impaction) and esophageal eosinophilia ≥ 15 eos/HPF. All patients were re-evaluated on PPI therapy during follow-up. RESULTS: A total of 137 patients were diagnosed with EoE during the study period, of whom 63 (46%) achieved clinicohistologic remission on PPI therapy. The prevalence of autoimmune disorders was low. Mean incidence rate was 8.09 new cases/100,000 inhabitants/year, increasing to 9.95 during the last lustrum and peaking in 2016 with 13.7. This trend coincided with late declining of esophageal biopsies rate. Overall prevalence in 2016 was 81.73 patients/100,000 inhabitants, with the highest prevalence in males between age 35 and 44 years (273 cases/100,000). No seasonal variation was observed in the diagnosis of EoE (53% during pollen season vs. 47%, p = 0.4). CONCLUSIONS: In midwestern Spain, incidence (13.7 cases/100,000 inhabitants/year) and prevalence (81.73 patients/100,000 inhabitants) in 2016 have grown remarkably in just one decade, coming closer to those figures recently reported for Crohn's disease in Spain.
OBJECTIVES: Epidemiologic studies on eosinophilic esophagitis (EoE) are scarce and patient responders to proton pump inhibitor (PPI) therapy have usually been excluded. We aimed to evaluate population-based incidence rates, prevalence and trends in adult EoE over the past decade, including responders to PPI therapy. METHODS: We conducted an analysis of a prospectively established case registry in the health area of Cáceres, located in midwestern Spain. From the first EoE case diagnosed in 2007, endoscopy and pathology reports up to December 2016 were manually reviewed. A baseline diagnosis of EoE was confirmed upon symptoms of esophageal dysfunction (dysphagia/food impaction) and esophageal eosinophilia ≥ 15 eos/HPF. All patients were re-evaluated on PPI therapy during follow-up. RESULTS: A total of 137 patients were diagnosed with EoE during the study period, of whom 63 (46%) achieved clinicohistologic remission on PPI therapy. The prevalence of autoimmune disorders was low. Mean incidence rate was 8.09 new cases/100,000 inhabitants/year, increasing to 9.95 during the last lustrum and peaking in 2016 with 13.7. This trend coincided with late declining of esophageal biopsies rate. Overall prevalence in 2016 was 81.73 patients/100,000 inhabitants, with the highest prevalence in males between age 35 and 44 years (273 cases/100,000). No seasonal variation was observed in the diagnosis of EoE (53% during pollen season vs. 47%, p = 0.4). CONCLUSIONS: In midwestern Spain, incidence (13.7 cases/100,000 inhabitants/year) and prevalence (81.73 patients/100,000 inhabitants) in 2016 have grown remarkably in just one decade, coming closer to those figures recently reported for Crohn's disease in Spain.
Authors: E S Dellon; R Erichsen; J A Baron; N J Shaheen; M Vyberg; H T Sorensen; L Pedersen Journal: Aliment Pharmacol Ther Date: 2015-02-12 Impact factor: 8.171
Authors: Alberto Fernández; Vicent Hernández; David Martínez-Ares; Luciano Sanromán; María Luisa de Castro; Juan Ramón Pineda; Amalia Carmona; Carlos González-Portela; Carlos Salgado; Jesús Martínez-Cadilla; Santos Pereira; Jose Ignacio García-Burriel; Santiago Vázquez; Ignacio Rodríguez-Prada Journal: Gastroenterol Hepatol Date: 2015-04-15 Impact factor: 2.102
Authors: Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2011-04-07 Impact factor: 10.793
Authors: Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg Journal: Gastroenterology Date: 2007-08-08 Impact factor: 22.682
Authors: B Giriens; P Yan; E Safroneeva; M Zwahlen; A Reinhard; A Nydegger; S Vavricka; C Sempoux; A Straumann; A M Schoepfer Journal: Allergy Date: 2015-09-13 Impact factor: 13.146
Authors: Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Glenn T Furuta; Chris A Liacouras; David A Katzka Journal: Am J Gastroenterol Date: 2013-04-09 Impact factor: 10.864
Authors: Kathryn Peterson; Rafael Firszt; John Fang; Jathine Wong; Ken R Smith; Kristina A Brady Journal: Am J Gastroenterol Date: 2016-05-24 Impact factor: 10.864
Authors: Willemijn E de Rooij; Marielle E Barendsen; Marijn J Warners; Bram D van Rhijn; Joanne Verheij; Annette H Bruggink; Albert J Bredenoord Journal: Neurogastroenterol Motil Date: 2021-01-10 Impact factor: 3.598